Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Madrigal Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Madrigal Pharmaceuticals wird ein jährliches Gewinn- und Umsatzwachstum von 64.3% bzw. 55.7% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 64.3% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -138.5% betragen.

Wichtige Informationen

64.3%

Wachstumsrate der Gewinne

64.3%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.8%
Wachstumsrate der Einnahmen	55.7%
Zukünftige Eigenkapitalrendite	-138.5%
Analystenabdeckung	Good
Zuletzt aktualisiert	05 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage

Apr 24

Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge

Mar 15

Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's Potential

Feb 07

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Could Be 45% Below Their Intrinsic Value Estimate

May 11

Madrigal: NASH Data In Q4 Is The Key

Apr 19

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Feb 24

Madrigal: Delayed NASH Data Is Positive But Real Tests Are Still To Come

Jan 31

Madrigal: Powerful Catalyst Approaching

Jan 09

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Nov 08

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Jul 26

Madrigal Pharmaceuticals: Leading The NASH Innovation

May 05

Here's Why We're Watching Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Situation

Apr 12

We Think Madrigal Pharmaceuticals (NASDAQ:MDGL) Can Afford To Drive Business Growth

Dec 28

Madrigal Pharma: A Look At The Early MAESTRO Trial Data

Nov 27

Madrigal Pharmaceuticals (MDGL) Presents At AASLD 2020 Conference- Slideshow

Nov 17

Madrigal Pharmaceuticals EPS misses by $0.40

Nov 05

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:MDGL - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	959	98	-172	-194	13
12/31/2025	361	-403	-434	-545	14
12/31/2024	76	-583	-590	-574	15
3/31/2024	N/A	-444	-391	-389	N/A
12/31/2023	N/A	-374	-326	-324	N/A
9/30/2023	N/A	-347	-303	-303	N/A
6/30/2023	N/A	-330	-277	-277	N/A
3/31/2023	N/A	-315	-259	-259	N/A
12/31/2022	N/A	-295	-225	-225	N/A
9/30/2022	N/A	-274	-215	-214	N/A
6/30/2022	N/A	-256	-201	-201	N/A
3/31/2022	N/A	-247	-191	-190	N/A
12/31/2021	N/A	-242	-184	-184	N/A
9/30/2021	N/A	-236	-191	-191	N/A
6/30/2021	N/A	-231	-193	-193	N/A
3/31/2021	N/A	-219	-171	-170	N/A
12/31/2020	N/A	-202	-158	-158	N/A
9/30/2020	N/A	-171	-115	-115	N/A
6/30/2020	N/A	-134	-79	-78	N/A
3/31/2020	N/A	-105	-66	-66	N/A
12/31/2019	N/A	-84	-42	-42	N/A
9/30/2019	N/A	-68	-36	-36	N/A
6/30/2019	N/A	-55	-30	-30	N/A
3/31/2019	N/A	-42	-23	-23	N/A
12/31/2018	N/A	-33	-26	-26	N/A
9/30/2018	N/A	-30	-25	-25	N/A
6/30/2018	N/A	-30	-25	-25	N/A
3/31/2018	N/A	-32	-27	-27	N/A
12/31/2017	N/A	-31	N/A	-22	N/A
9/30/2017	N/A	-30	N/A	-22	N/A
6/30/2017	N/A	-36	N/A	-26	N/A
3/31/2017	N/A	-31	N/A	-21	N/A
12/31/2016	N/A	-26	N/A	-18	N/A
9/30/2016	N/A	-21	N/A	-13	N/A
6/30/2016	N/A	-8	N/A	-5	N/A
3/31/2016	N/A	-7	N/A	-3	N/A
12/31/2015	N/A	-7	N/A	-3	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: MDGL wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.4%).

Ertrag vs. Markt: MDGL wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: MDGL wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: MDGLDie Einnahmen des Unternehmens (55.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.4% pro Jahr).

Hohe Wachstumseinnahmen: MDGLDie Einnahmen des Unternehmens (55.7% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: MDGL wird voraussichtlich in 3 Jahren unrentabel sein.

Madrigal Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Forecast to breakeven in 2026

No longer forecast to breakeven

Consensus EPS estimates fall by 11%

Price target increased by 18% to US$383

Consensus revenue estimates fall by 14%

Forecast breakeven date pushed back to 2026

Recent updates

Independent Lead Director notifies of intention to sell stock

Forecast to breakeven in 2026

No longer forecast to breakeven

Madrigal Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Madrigal Pharmaceuticals, Inc., Annual General Meeting, Jun 25, 2024

Madrigal Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage

Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis

Independent Director notifies of intention to sell stock

Madrigal Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $599.999764 million.

Madrigal Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $599.999764 million.

Consensus EPS estimates fall by 11%

Price target increased by 18% to US$383

Madrigal Pharmaceuticals, Inc. Announces FDA Approval of Rezdiffra™ (Resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (Nash) with Moderate to Advanced Liver Fibrosis

Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge

Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis

Madrigal Pharmaceuticals, Inc. Announces Management Changes

Madrigal Pharmaceuticals, Inc. Appoints CFO Changes

Consensus revenue estimates fall by 14%

Forecast breakeven date pushed back to 2026

New minor risk - Share price stability

Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine

Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's Potential

Madrigal Pharmaceuticals, Inc. Announces Additions to its Leadership Team

Insider exercised options and sold US$513k worth of stock

Senior VP & General Counsel exercised options and sold US$894k worth of stock

Madrigal Pharmaceuticals, Inc. Appoints Ronald Filippo as Chief Information Officer

Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer

New major risk - Financial position

Madrigal Pharmaceuticals, Inc. Announces the Resignation of Remy Sukhija as Chief Commercial Officer

Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of Nash with Liver

Madrigal Pharmaceuticals, Inc. Announces Chief Executive Officer Changes

Madrigal Pharmaceuticals, Inc. Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis

Price target increased by 7.4% to US$341

Insider exercised options and sold US$1.9m worth of stock

Consensus revenue estimates fall by 92%

Independent Director exercised options and sold US$4.3m worth of stock

Senior VP & General Counsel exercised options and sold US$2.5m worth of stock

Madrigal Pharmaceuticals, Inc. Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of Nash with Liver Fibrosis

Forecast to breakeven in 2025

Madrigal Pharmaceuticals, Inc. announced that it has received $90 million in funding

Madrigal Pharmaceuticals, Inc. Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis

Calculating The Intrinsic Value Of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

Price target increased to US$164

Insufficient new directors

Madrigal Pharmaceuticals Initiates the MAESTRO-NASH Outcomes Study Evaluating Resmetirom for the Treatment of Patients with Compensated NASH Cirrhosis

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Madrigal: Buy And Hoard Before Q4 Data Readout

Madrigal cut to Neutral at B. Riley on concerns over upcoming NASH readout

Madrigal Pharmaceuticals, Inc. Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Could Be 45% Below Their Intrinsic Value Estimate

Madrigal Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

Insufficient new directors

Madrigal: NASH Data In Q4 Is The Key

Madrigal Pharmaceuticals Provides Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial Results

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Madrigal Pharmaceuticals, Inc. Announces Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures of Liver and Cardiovascular Health

Madrigal: Delayed NASH Data Is Positive But Real Tests Are Still To Come

Madrigal Pharmaceuticals to Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom

Madrigal: Powerful Catalyst Approaching

Madrigal Pharmaceuticals, Inc. Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Madrigal Pharmaceuticals, Inc. Offers Patients Resmetirom in Open Label Active Treatment Extension of the Phase 3 MAESTRO-NAFLD-1 Clinical Study

Madrigal Pharmaceuticals Completes Enrollment of the 52 Week Liver Biopsy Patient Population in the Phase 3 MAESTRO-NASH Study of Resmetirom

Madrigal Pharmaceuticals Announces Presentation of Positive Clinical Data of Resmetirom from Open-Label Portion of Ongoing Phase 3 Clinical Trial Maestro-Nafld-1

Madrigal Pharmaceuticals: Leading The NASH Innovation

Here's Why We're Watching Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Situation

New 90-day low: US$110